MARC Record from harvard_bibliographic_metadata

LEADER: 04900cam a22004934a 4500
001 011399533-4
005 20120507171249.0
008 051216s2006 nyua b 001 0 eng
010 $a 2005036791
016 7 $a101263798$2DNLM
020 $a0849327792 (alk. paper)
020 $a9780849327797
035 0 $aocm62736887
040 $aDNLM/DLC$cDLC$dNLM$dBAKER$dC#P$dYDXCP$dOCLCQ$dMUQ$dDLC
042 $apcc
050 00 $aRM301.25$b.S55 2006
060 00 $a2006 K-070
060 10 $aQV 744$bP9645 2006
082 00 $a615/.19$222
245 04 $aThe process of new drug discovery and development /$cedited by Charles G. Smith, James T. O'Donnell.
250 $a2nd ed.
260 $aNew York :$bInforma Healthcare,$cc2006.
300 $a668 p. :$bill. ;$c27 cm.
500 $aRev. ed. of: The process of new drug discovery and development / Charles G. Smith. c1992.
504 $aIncludes bibliographical references and index.
505 0 $aOverview of the current process of new drug discovery and development / Charles G. Smith and James T. O'Donnell -- Integrated drug product development: from lead candidate selection to life-cycle management / Madhu Pudipeddi, Abu T.M. Serajuddin, and Daniel Mufson -- The impact of combinatorial chemistry on drug discovery / Michael H. Rabinowitz and Nigel Shankley -- High-throughput screening: enabling and influencing the process of drug discovery / Carol Ann Homon and Richard M. Nelson -- Pharmacological and pharmaceutical profiling: new trends / Joanne Bowes ... [et al.] -- Cell-based analysis of drug response using moving optical gradient fields / Jeff M. Hall ... [et al.].
505 8 $aPatient-derived primary cells in high-throughput differential antitumor screens: let the patients be the guide / Irwin A. Braude -- The evolving role of the caco-2 cell model to estimate intestinal absorption potential and elucidate transport mechanisms / Jibin Li and Ismael J. Hidalgo -- The promise of metabonomics in drug discovery / Harold J. Kwalwasser and Pauline Gee -- Pharmacogenetics and pharmacogenomics in drug development and regulatory decision-making: report of the first FDA-PWG-PhRMA-druSafe workshop / Lawrence J. Lesko ... [et al.].
505 8 $aDrugs from molecular targets for CNS and neurodegenerative diseases / William T. Comer and Gönül Veliçelebi -- Safety pharmacology / Jean-Pierre Valentin and Tim G. Hammond -- Nonclinical drug safety assessment / Frederick E. Reno -- Preclinical genotoxicity testing: past, present and future / Richard H.C. San -- The need for animals in biomedical research / Charles G. Smith -- Defining the actual research approach to the new drug substance / Charles G. Smith -- Pharmacokinetics: pharmacodynamics in new drug development / Sarfaraz K. Niazi.
505 8 $aPharmaceutics and compounding issues in new drug development and marketing / Loyd V. Allen -- Late stage and process development activities / Charles G. Smith -- Contract research organizations: role and function in new drug development / F. Richard Nichol -- The front lines of clinical research: the industry / Lori Nesbitt -- Horizons for cancer chemotherapy (and nonchemotherapy) / Daniel D. Von Hoff -- Human immunodeficiency virus/acquired immune deficiency syndrome: clinical testing challenges / Vincent Idemyor -- Common technical document: the changing face of the new drug application / Justina A. Molzon.
505 8 $aElectronic publishing / Heather L. Wallace -- The important role of pharmacists in a complex risk-management system: managing the risks from medical product use by focusing on patient education, monitoring, and adverse event reporting / Justina A. Molzon -- Liability, litigation, and lessons in new drug development / James T. O'Donnell -- Problems in the nondrug marketplace / Stephen Barrett -- Patents and new product development in the pharmaceutical and biotechnology industries / Henry Grabowski -- The pharmaceutical revolution: drug discovery and development / John C. Somberg -- The discovery of Rituxan / Mitchell E. Reff.
505 8 $aFunding the birth of a drug: lessons from the sell side / Howard E. Greene -- Innovations for the drug development pathway: what is needed now / Janet Woodcock -- Managing R & D uncertainty and maximizing the commercial potential of pharmaceutical compounds using the dynamic modeling framework / Mark Paich ... [et al.].
650 0 $aDrugs$xResearch.
650 0 $aDrugs$xDesign.
650 12 $aDrug Design.
650 22 $aDrug Evaluation, Preclinical.
650 22 $aDrug Evaluation.
650 0 $aDrugs$xResearch$xHistory.
650 0 $aDrugs$xDesign$xHistory.
655 7 $aHistory.$2fast
700 1 $aSmith, Charles G.$q(Charles Giles).$tProcess of new drug discovery and development.
700 1 $aSmith, Charles G.$q(Charles Giles)
700 1 $aO'Donnell, James,$cPharm. D.
988 $a20080304
906 $0OCLC